Studybox Research 510(k) Clinical Studies
Fentanyl Urine Screen
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Fentanyl is not detected by traditional opiate immunoassays, which target morphine-like structures, and the rise of illicitly manufactured fentanyl created demand for dedicated screens. The clinical study follows the drugs-of-abuse model, mass spectrometry confirmation on every specimen and agreement by concentration stratum around the cutoff, with two fentanyl-specific complications: fentanyl is rapidly metabolized so that norfentanyl often predominates in urine, and the illicit supply contains analogs whose cross-reactivity with the antibody varies.
The comparator definition therefore matters. A device that detects fentanyl but not norfentanyl will miss specimens from people whose last use was more than a day earlier, and the protocol should state whether agreement is assessed against fentanyl, norfentanyl or either. Positives come from emergency departments and treatment programs, and legitimately prescribed fentanyl (patches, perioperative use) produces true positives that labeling must address.
- Analyte
- Fentanyl and its primary metabolite norfentanyl at a defined cutoff concentration
- Therapeutic area
- Drugs of Abuse
- Specimens
- Urine
- Intended-use settings
- physician office, urgent care, emergency department, home use
- Operators
- Non-laboratory staff in emergency departments, treatment programs, urgent care and physician offices with waived certificates; lay users for over-the-counter versions.
- Comparator
- Typically LC-MS/MS quantitation of fentanyl and norfentanyl, with results classified relative to the device cutoff.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The confirmatory target(s) and cutoff(s) for fentanyl and norfentanyl must be specified in advance and agreement reported against that definition; labeling states which compound the cutoff refers to.
- Cross-reactivity against a panel of fentanyl analogs and against other opioids is a core analytical dataset, and the analogs tested should reflect current drug supply surveillance.
- Near-cutoff strata are typically filled with characterized specimens because prospective specimens cluster at high concentrations in active-use populations.
Endpoints the study must support
- Percent agreement with LC-MS/MS stratified by concentration relative to the cutoff
- Precision near the cutoff using characterized or spiked specimens
- Cross-reactivity with fentanyl analogs and structurally unrelated opioids, and interference from common medications
- Untrained operator and, for over-the-counter claims, lay user agreement
Enrollment realities
Driven by confirmed positives near the cutoff, which are uncommon prospectively because active-use specimens are typically far above it; characterized specimens fill the gap. Emergency department and treatment program sites supply high-concentration positives quickly.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
FAQ
Fentanyl Urine Screen Study Questions.
01 Who operates the fentanyl urine screen in a 510(k) studies study?
Non-laboratory staff in emergency departments, treatment programs, urgent care and physician offices with waived certificates; lay users for over-the-counter versions.
02 What is the comparator for a fentanyl urine screen study?
Typically LC-MS/MS quantitation of fentanyl and norfentanyl, with results classified relative to the device cutoff.
03 What drives enrollment for a fentanyl urine screen study?
Driven by confirmed positives near the cutoff, which are uncommon prospectively because active-use specimens are typically far above it; characterized specimens fill the gap. Emergency department and treatment program sites supply high-concentration positives quickly.
Let's talk IVD research
Planning a fentanyl urine screen study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.